Literature DB >> 21592521

Impact of antipsychotics on cytokine production in-vitro.

Hubertus Himmerich1, Jeremias Schönherr, Stephany Fulda, Abigail J Sheldrick, Katrin Bauer, Ulrich Sack.   

Abstract

OBJECTIVE: A growing body of data from genetic, immunological and clinical studies indicates an involvement of the immune system in the pathophysiology of schizophrenia and suggests that the modulation of the cytokine system by antipsychotics may be one cause for the improvement of psychotic symptoms. However, the influence of the typical antipsychotics chlorpromazine and haloperidol, and the effect of typical and atypical antipsychotics on the TSST-1-stimulated blood cell secretion of cytokines, and specifically the interleukin (IL)-17 production have not been studied so far, although IL-17 is a leading pro-inflammatory cytokine.
METHOD: We measured levels of IL-1β, IL-2, IL-4, IL-6, IL-17 and tumor necrosis factor-α (TNF-α) in stimulated blood of 10 healthy female subjects in a whole blood assay using the toxic shock syndrome toxin TSST-1 as stimulant. Blood was either supplemented with antipsychotics (chlorpromazine, haloperidol, clozapine, N-desmethylclozapine and quetiapine with four different concentrations each) or not.
RESULTS: Under TSST-1 stimulation, antipsychotics as a group had no influence on IL-1β or IL-6 concentrations but increased IL-4 levels. The most consistent findings were seen regarding IL-17. Mean IL-17 concentrations differed significantly between blood with and without antipsychotic supplements and were increased over all antipsychotics and almost all of the applied antipsychotic concentrations. TNF-α levels were increased by chlorpromazine; N-desmethylclozapine and quetiapine reduced IL-2 production.
CONCLUSIONS: Antipsychotics might, among other mechanisms, act as such by increasing the production of IL-17.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21592521     DOI: 10.1016/j.jpsychires.2011.04.009

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  27 in total

Review 1.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

Review 2.  The cytokine model of schizophrenia: emerging therapeutic strategies.

Authors:  Ragy R Girgis; Samhita S Kumar; Alan S Brown
Journal:  Biol Psychiatry       Date:  2013-12-11       Impact factor: 13.382

Review 3.  Viral infection, inflammation and schizophrenia.

Authors:  Rachel E Kneeland; S Hossein Fatemi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-10       Impact factor: 5.067

Review 4.  Immune-based strategies for mood disorders: facts and challenges.

Authors:  Gabriela D Colpo; Marion Leboyer; Robert Dantzer; Mahdukar H Trivedi; Antonio L Teixeira
Journal:  Expert Rev Neurother       Date:  2017-11-27       Impact factor: 4.618

5.  Interleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis.

Authors:  Xinyu Fang; Yi Zhang; Weixing Fan; Wei Tang; Chen Zhang
Journal:  Mol Neuropsychiatry       Date:  2017-10-28

6.  Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Tracy L Greer; Taryn L Mayes; Madhukar H Trivedi
Journal:  Brain Behav Immun       Date:  2017-07-08       Impact factor: 7.217

7.  Eosinophilia and parotitis occurring early in clozapine treatment.

Authors:  Bochra Nourhène Saguem; Saoussen Bouhlel; Chaker Ben Salem; Bechir Ben Hadj Ali
Journal:  Int J Clin Pharm       Date:  2015-09-15

8.  Selective Immunoglobulin M Deficiency Among Clozapine-Treated Patients: A Nested Case-Control Study.

Authors:  Roberto Lozano; Reyes Marin; Maria-Jesus Santacruz; Asunción Pascual
Journal:  Prim Care Companion CNS Disord       Date:  2015-07-02

9.  A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia.

Authors:  Ragy R Girgis; Adam Ciarleglio; Tse Choo; Gregory Haynes; Joan M Bathon; Serge Cremers; Joshua T Kantrowitz; Jeffrey A Lieberman; Alan S Brown
Journal:  Neuropsychopharmacology       Date:  2017-11-01       Impact factor: 7.853

10.  Impact of lithium alone and in combination with antidepressants on cytokine production in vitro.

Authors:  Charlotte Petersein; Ulrich Sack; Roland Mergl; Jeremias Schönherr; Frank M Schmidt; Nicole Lichtblau; Kenneth C Kirkby; Katrin Bauer; Hubertus Himmerich
Journal:  J Neural Transm (Vienna)       Date:  2014-11-07       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.